A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC 736511, IND 74019) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Pemetrexed (Primary) ; Sunitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Dec 2017 Status changed from active, no longer recruiting to completed.
- 06 Sep 2012 Planned End Date changed from 1 Aug 2010 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 25 Jun 2012 Primary endpoint 'Progression-free-survival-rate' has not been met.